| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8284618 | Maturitas | 2011 | 8 Pages |
Abstract
The results of the LIBERATE trial show that tibolone is effective in symptomatic breast cancer patients and improves their quality of life. However, this finding should be judged within the context of the main outcome of the trial, showing that tibolone increases the risk of recurrence. The use of tibolone in women with breast cancer will remain contraindicated and any off-label use incurs a now proven risk.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Piero Sismondi, Rainer Kimmig, Ernst Kubista, Nicoletta Biglia, Jan Egberts, Roel Mulder, Juan Planellas, Giulia Moggio, Mirjam Mol-Arts, Peter Kenemans,